RIL
FHTX icon

Rothschild Investment LLC’s Foghorn Therapeutics FHTX Stock Holding History

Rothschild Investment LLC’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161 Sell
33
-1
-3% -$4 ﹤0.01% 3469
2026
Q1 		$163 Buy
+34
New +$187 ﹤0.01% 3333

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Rothschild Investment LLC's FHTX Position: Q2 2026 in Review

Rothschild Investment LLC reduced its Foghorn Therapeutics (FHTX) stake by 2.9% in Q2 2026, selling an estimated $4 and leaving 33 shares worth $161. The position accounts for ﹤0.01% of the portfolio, ranked #3469.

Rothschild Investment LLC first reported a position in FHTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $163 in Q1 2026. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Rothschild Investment LLC held 33 shares of Foghorn Therapeutics worth $161 as of Q2 2026.
  • Rothschild Investment LLC sold 1 Foghorn Therapeutics share in Q2 2026, an estimated $4.
  • Foghorn Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3469 holding.
  • Rothschild Investment LLC first reported a position in Foghorn Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Rothschild Investment LLC's Foghorn Therapeutics position peaked at $163 in Q1 2026.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.